Hims & Hers Health, Inc. $HIMS Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 74.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 143,287 shares of the company’s stock after acquiring an additional 61,195 shares during the period. Intech Investment Management LLC’s holdings in Hims & Hers Health were worth $4,234,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. UMB Bank n.a. grew its position in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after acquiring an additional 933 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at about $41,000. Larson Financial Group LLC grew its position in shares of Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after acquiring an additional 458 shares during the period. Tsfg LLC acquired a new stake in shares of Hims & Hers Health during the 1st quarter valued at about $46,000. Finally, Fifth Third Bancorp grew its position in shares of Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock valued at $46,000 after acquiring an additional 961 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

HIMS has been the topic of a number of analyst reports. Truist Financial dropped their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research report on Monday, August 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a research note on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Trading Up 7.2%

HIMS opened at $55.48 on Friday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The company’s 50 day simple moving average is $50.26 and its two-hundred day simple moving average is $45.25. Hims & Hers Health, Inc. has a 1-year low of $15.73 and a 1-year high of $72.98. The firm has a market capitalization of $12.54 billion, a price-to-earnings ratio of 69.35, a price-to-earnings-growth ratio of 3.50 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million during the quarter, compared to analysts’ expectations of $550.06 million. During the same period last year, the business earned $0.06 earnings per share. The company’s revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total value of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at $9,105,385.20. This trade represents a 26.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Oluyemi Okupe sold 23,107 shares of the firm’s stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. This trade represents a 26.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,384,728 shares of company stock valued at $71,149,098. Company insiders own 13.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.